The Pharmacology of mTOR Inhibition

被引：467

作者：

Guertin, David A. ^{[1
]}

Sabatini, David M. ^{[1
,2
,3
]}

机构：

[1] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02141 USA

[2] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA

[3] MIT, Koch Ctr Integrat Canc Res, Cambridge, MA 02139 USA

来源：

SCIENCE SIGNALING | 2009年 / 2卷 / 67期

关键词：

PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; MAMMALIAN TARGET; COMPLEX; RAPAMYCIN INHIBITOR; CELL-GROWTH; RAG GTPASES; RICTOR; PHOSPHORYLATION; CANCER; RAPTOR;

D O I：

10.1126/scisignal.267pe24

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)-based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.

引用

页数：6

共 36 条

[1] Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation
Barquilla, Antonio
Crespo, Jose L.
Navarro, Miguel
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (38) : 14579 - 14584
[2] Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex
Beevers, Christopher S.
Chen, Long
Liu, Lei
Luo, Yan
Webster, Nicholas J. G.
Huang, Shile
[J]. CANCER RESEARCH, 2009, 69 (03) : 1000 - 1008
[3] Skeletal Muscle-Specific Ablation of raptor, but Not of rictor, Causes Metabolic Changes and Results in Muscle Dystrophy
Bentzinger, C. Florian
Romanino, Klaas
Cloetta, Dimitri
Lin, Shuo
Mascarenhas, Joseph B.
Oliveri, Filippo
Xia, Jinyu
Casanova, Emilio
Costa, Celine F.
Brink, Marijke
Zorzato, Francesco
Hall, Michael N.
Rueegg, Markus A.
[J]. CELL METABOLISM, 2008, 8 (05) : 411 - 424
[4] Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Choo, Andrew Y.
Yoon, Sang-Oh
Kim, Sang Gyun
Roux, Philippe P.
Blenis, John
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) : 17414 - 17419
[5] TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
Copp, Jeremy
Manning, Gerard
Hunter, Tony
[J]. CANCER RESEARCH, 2009, 69 (05) : 1821 - 1827
[6] S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth
Dorrello, N. Valerio
Peschiaroli, Angelo
Guardavaccaro, Daniele
Colburn, Nancy H.
Sherman, Nicholas E.
Pagano, Michele
[J]. SCIENCE, 2006, 314 (5798) : 467 - 471
[7] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, Jeffrey A.
Chen, Liang
Tan, Xiaohong
Crosby, Katherine
Guimaraes, Alexander R.
Upadhyay, Rabi
Maira, Michel
McNamara, Kate
Perera, Samanthi A.
Song, Youngchul
Chirieac, Lucian R.
Kaur, Ramneet
Lightbown, Angela
Simendinger, Jessica
Li, Timothy
Padera, Robert F.
Garcia-Echeverria, Carlos
Weissleder, Ralph
Mahmood, Umar
Cantley, Lewis C.
Wong, Kwok-Kin
[J]. NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
[8] Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, Morris E.
Apsel, Beth
Uotila, Aino
Loewith, Robbie
Knight, Zachary A.
Ruggero, Davide
Shokat, Kevan M.
[J]. PLOS BIOLOGY, 2009, 7 (02) : 371 - 383
[9] mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
Garcia-Martinez, Juan M.
Alessi, Dario R.
[J]. BIOCHEMICAL JOURNAL, 2008, 416 : 375 - 385
[10] Defining the role of mTOR in cancer
Guertin, David A.
Sabatini, David M.
[J]. CANCER CELL, 2007, 12 (01) : 9 - 22

← 1 2 3 4 →